Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Adv Nanobiomed Res. 2021 Mar 13;1(8):2100021. doi: 10.1002/anbr.202100021

Figure 1. Schematic of the mechanism of action of the CpG-PBNP-PTT-based nanoimmunotherapy in the TH-MYCN model of neuroblastoma (NB).

Figure 1.

The CpG-PBNP-PTT-based nanoimmunotherapy mediates tumor cell priming along with immunogenic cell death (ICD) administered at a specific thermal dose, leading to T cell activation and generation of potent T cell memory, which can elicit long-term, tumor-free survival, and rejection of tumor rechallenge in a TH-MYCN model of NB. Further, the nanoimmunotherapy generates a potent abscopal effect, which slowers the progression of distal, untreated tumors enhancing the survival in the TH-MYCN NB model.